This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Doussis-Anagnostopoulou, I. A. Articles by Pangalis, G. A. Search for Related Content PubMed PubMed Citation Articles by Doussis-Anagnostopoulou, I. A. Articles by Pangalis, G. A.

Topoisomerase II Expression as an Independent Prognostic Factor in Hodgkin's Lymphoma

Authors' Affiliations: ¹ Laboratory of Histology and Embryology, ² First Department of Internal Medicine and Department of Haematology and ³ Department of Pathology, National and Kapodistrian University of Athens, Medical School, Athens, Greece

Requests for reprints: Ipatia Doussis-Anagnostopoulou, Laboratory of Histology and Embryology, Athens Medical School, 75, Micras Asias str., 11527 Goudi, Athens, Greece. Phone: 0030-210-7462348/0030-210-6717049; E-mail: ipatiada{at}med.uoa.gr.

Purpose: To correlate the immunohistochemical expression of topoisomerase II (topoII) in Hodgkin's lymphoma (HL) with clinicopathological parameters, the expression of Ki-67 and the outcome of patients, who had been homogenously treated with ABVD or equivalent regimens.

Experimental Design: Immunohistochemistry using the monoclonal antibody Ki-S1 (topoII) was performed in 238 HL patients. MiB1 (Ki-67) expression was evaluated in 211/238.

Results: The mean ± SD percentage of topoII- and Ki-67–positive Hodgkin-Reed-Sternberg (HRS) cells was 63 ± 19% (5%-98%) and 73 ± 19% (8%-99%), respectively. The median percentage of topoII-positive HRS cells was 64% (interquartile range, 51-78%). There was no correlation between topoII expression and patient characteristics. TopoII and Ki-67 expression were correlated (Spearman's Rho 0.255, P < 0.001). TopoIl expression within the highest quartile of this patient population was predictive of failure free survival (FFS) (10-year rates 82 ± 3% vs 68 ± 7%, P = 0.02 for patients falling into the quartiles 1-3 and 4 respectively). In multivariate analysis topoII expression was independently predictive of FFS.

Conclusion: TopoII was expressed in all cases of HL showing a correlation with Ki-67 expression. Under current standard therapy including drugs inhibiting its activity, topoII was an independent adverse predictor of FFS with no statistically significant correlation with other established prognostic factors.

This article has been cited by other articles:

				B. Chetaille, F. Bertucci, P. Finetti, B. Esterni, A. Stamatoullas, J. M. Picquenot, M. C. Copin, F. Morschhauser, O. Casasnovas, T. Petrella, et al. Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome Blood, March 19, 2009; 113(12): 2765 - 3775. [Abstract] [Full Text] [PDF]